Most Patients With Care Plan Die in Chosen Location

Share this content:
Most Patients With Care Plan Die in Chosen Location
Most Patients With Care Plan Die in Chosen Location

TUESDAY, Aug. 15, 2017 (HealthDay News) -- Most individuals with a Coordinate My Care (CMC) plan die in their chosen location, according to a research letter published online Aug. 15 in the Annals of Internal Medicine.

Thomas Callender, M.B.Ch.B., from the Royal Marsden NHS Foundation Trust and Imperial College London, and colleagues analyzed determinants of achieving preferred place of death to derive clinically relevant approaches associated with more persons realizing their wishes. Data were included for all persons older than 18 years with a CMC plan and a recorded place of death.

The researchers analyzed 9,027 patients, of whom 77.5 percent died in their chosen location. Overall, 97.8 percent preferred to die in the nonacute sector, defined as at home, a care home, or hospice. A total of 73.8, 89.7, and 67.6 percent of those who cited their home, a care home, and hospice as their first choice of place of death achieved their wish, respectively. More persons with cancer chose to die in a hospice than those with other diagnoses (16.6 versus 2.8 percent). More than half (55.3 percent) of those who did not die in their preferred place died in a hospital. Females, those with poor performance status, and patients with a diagnosis of cancer were more likely to die in their chosen location.

"Further research is needed to explore how best to improve the proportion of persons who discuss advance care planning with their clinicians and to overcome perceived barriers to these conversations," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »